We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Plaintiff’s federal securities class action complaint alleged that Savient Pharmaceuticals, Inc. and two of its officers failed to disclose that 5 of the patients in a clinical trial of Krystexxa, Savient’s new drug, suffered serious side effects
Defendant was indicted for engaging in a "cherry-picking" scheme under which "he executed trades without immediately assigning them to a particular account."
